Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma

Table 1

Baseline characteristics of the patients.

Characteristics	No. of patients (%)
	PD-1 blockade alone	PD-1 blockade-based combination	value
Gender			0.764
Male	17 (33.3%)	7 (13.7%)
Female	21 (41.2%)	6 (11.8%)
Age, mean (range)	56 (28–81)	51 (28–69)	0.212
ECOG status			0.176
0–1	26 (50.9%)	6 (11.8%)
≥2	12 (23.5%)	7 (13.7%)
Primary sites			0.979
Acral	12 (23.5%)	4 (7.8%)
Mucosal	13 (25.5%)	4 (7.8%)
CSD/non-CSD	13 (25.5%)	5 (9.8%)
Metastatic sites
Liver	9 (17.6%)	6 (11.8%)	0.176
Lung	16 (31.4%)	6 (11.8%)	0.611
Bone	9 (17.6%)	3 (5.9%)	0.864
Brain	5 (9.8%)	0 (0%)	0.153
Lymph nodes	25 (49.0%)	11 (21.6%)	0.16
LDH level			0.014
≤UNL	30 (58.8%)	5 (9.8%)
>UNL	8 (15.7%)	8 (15.7%)
CRP level			0.140
≤UNL	28 (54.9%)	6 (11.8%)
>UNL	10 (19.6%)	7 (13.7%)
ALB level			0.561
≥NLL	34 (66.7%)	12 (23.5%)
<NLL	4 (7.8%)	1 (2.0%)
NLR			0.574
≥2.3	16 (31.4%)	6 (11.8%)
<2.3	22 (43.1%)	7 (13.7%)
PLR			0.406
≥162.5	15 (29.4%)	7 (13.7%)
<162.5	23 (45.1%)	6 (11.8%)
BRAF V600E status			0.761
Mutation	9 (17.6%)	2 (3.9%)
Wild-type	14 (27.5%)	6 (11.8%)
Unknown	15 (29.4%)	5 (9.8%)
PD-1 blockade agents			0.189
Nivolumab	24 (47.1%)	6 (11.8%)
Pembrolizumab	14 (27.5%)	7 (13.7%)
Treatment-naïve			0.961
Yes	22 (43.1%)	8 (15.7%)
No	16 (31.4%)	5 (9.8%)

ECOG: Eastern Cooperative Oncology Group; CSD: chronic sun-damaged; LDH: lactate dehydrogenase; CRP: C-reactive protein; UNL: upper normal limit; LNL: lower normal limit; ALB: albumin. All values were two-tailed.